IRIS
LARONI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.955
Totale 7.955
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.955
Totale 7.955
Salva come PNG Salva come JPEG
Città #
Genova 5.668
Genoa 937
Rapallo 781
Vado Ligure 549
Bordighera 20
Totale 7.955
Salva come PNG Salva come JPEG
Nome #
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 195
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 185
Neuroprotective features of mesenchymal stem cells. 176
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 169
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 158
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 151
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 149
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 145
Three years of experience: the Italian registry and safety data update 142
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases 128
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 123
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. 119
T-cell trafficking in the central nervous system. 119
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 118
Teriflunomide treatment reduces B cells in patients with MS. 117
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. 116
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 114
Approved drugs for multiple sclerosis: The challenge of choice 112
Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity 111
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation 111
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study 110
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis 110
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod 110
A case of thyroiditis during natalizumab therapy for multiple sclerosis 107
Wernicke's syndrome during parenteral feeding: not an unusual complication. 105
Regulatory Functions of Natural Killer Cells in Multiple Sclerosis 104
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 104
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 103
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 103
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution 103
Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma? 102
Can we kill an extra bird with the same stone? 102
IL-27 imparts immunoregulatory function to human NK cell subsets. 101
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. 101
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 100
Mesenchymal stem cells as treatment for MS - progress to date. 99
Role of the innate immune system in the pathogenesis of multiple sclerosis. 97
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 92
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy 91
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 89
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 89
JCV-DNA testing during natalizumab treatment is complementary to anti-JCV antibodies for PML risk stratification 88
Epstein-Barr-negative MS: a true phenomenon? 86
Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. 85
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis 85
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 84
Dysregulation of regulatory CD56 (bright) NK cells/T cells interactions in multiple sclerosis 84
Enhancing natural killer cells is beneficial in multiple sclerosis - Yes 84
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 84
Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. 83
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL 80
Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey 80
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study 78
Long-term disability progression in primary progressive multiple sclerosis: A 15-year study 78
Health-related quality of life in multiple sclerosis: Effects of natalizumab 75
Natural killer cells are functionally defective in multiple sclerosis 71
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 71
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 71
Finger motor performance as a new quantitative clinical endpoint in multiple sclerosis 66
Impaired suppressor function of NK cells in multiple sclerosis 65
Assessing upper limb function in Multiple Sclerosis by an engineered glove 63
Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection 62
CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis 58
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 58
Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy 56
Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS 55
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments 55
Nonfunctional natural killer regulatory cells in multiple sclerosis 54
Impaired suppressor function of CD56bright NK cells in early multiple sclerosis 54
MESEMS: a randomized, double blind placebo-controlled cross-over study to evaluate safety and efficacy of intravenous administration of autologous mesenchymal stem cells in patients with multiple sclerosis 53
Interferon beta potentiates the therapeutic activity of mesenchymal stem cells 51
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 48
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 46
The short-chain fatty acid butyrate decreases the regulatory function of human natural killer cells and promotes their maturation 45
Hypothalamic AgRP neurons control hematopoiesis and lymphopoiesis and are activated in experimental MS 44
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 43
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study 43
Aging with multiple sclerosis: Clinical characterization of an elderly population, a cross-sectional study 41
The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis 40
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 40
Cyclophosphamide pulses therapy after natalizumab discontinuation in Multiple Sclerosis patients 39
To switch therapies in RRMS: why and when? A real-life multicentre study. 39
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 39
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 37
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives 37
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 37
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 36
Informing MS patients on treatment options: a consensus on the process of consent taking 36
Mesenchymal Stem/Stromal Cells for Multiple Sclerosis and Other Neurological Diseases 36
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 34
null 34
A pilot study comparing myelin measurements from [18F]-Florbetaben PET and quantitative T1 map imaging in multiple sclerosis (MS) 32
A real-world study of alemtuzumab in a cohort of Italian patients 32
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 32
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab 29
Magnetic Resonance Imaging Finding of Periodontal and Inferior Alveolar Nerve Inflammation in a Subject With Trigeminal Neuralgia 27
Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups 26
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 26
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: who gains from it? 25
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial 24
Totale 8.044
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.019
article - articoli 29.602
book - libri 0
conference - conferenze 198
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 219
Totale 60.038
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.701 0 0 0 0 175 247 305 188 187 324 228 47
2020/2021880 60 55 57 112 87 54 69 74 55 110 75 72
2021/20221.094 45 28 84 111 44 94 40 252 74 113 66 143
2022/2023960 99 74 15 78 149 163 6 67 171 15 102 21
2023/2024765 41 84 9 88 66 84 53 70 69 18 46 137
2024/2025643 104 214 96 158 71 0 0 0 0 0 0 0
Totale 8.299